China early test for cervical cancer vaccine vaccine expected to be 5 years after the listing

[/]: Beijing, Guangdong and Zhejiang's four hospitals will soon develop cervical cancer vaccine clinical trial and preliminary experiment. If the test is successful, the vaccine in China after 5 years.

Zhejiang University-affiliated hospital of obstetrics and gynaecology has now announced, Zhejiang Province is cervical cancer vaccine clinical research of preparatory work, and is in the province-wide open competition voluntary subject of healthy women. In addition, the two hospitals in Beijing and Guangzhou hospital was also positive preparation.

"The growth of tumors in the human body, currently clear etiology of the only cervical cancer. 2008 medicine Nobel Prize winner is confirmed by the human papilloma virus (HPV) and cervical cancer. "Zhejiang University affiliated hospital Michèle Science Branch, gliding East human papilloma virus infection is induced cervical precancerous lesions, cervical cancer and other genital lesions of a major factor. Including HPV16-and 18-has been identified as carcinogenic genotypes that can cause 85.5% of cervical cancer. HPV6-and 11-infection may cause 90% of genital warts.

China plans to carry out the test for cervical cancer vaccine, is used by the United States Merck Sharp and Dohme company upon this principle developed by the four HPV preventive vaccine. The vaccine in Europe and the United States has been proven safe and effective, and has included the United States, 107 countries and territories on a large scale application. Some of the numerous countries such as Australia's women can also be vaccinated. Hong Kong area can also be vaccinated this vaccine, the vaccine price is approximately $ 3000 a needle.

"Follow the study design, study of half of the women's participation in the project start, vaccination, and the other half of the women you try a placebo, but the hospital after the listing of the vaccine and immunization supplement to them. "Gliding East, formal experiment will begin in early March, the completion time is approximately 30 months. Volunteers first needle inoculation with a vaccine, then the second and sixth months, additional vaccination respectively. Women participating in the project free of charge vaccinated and regularly undergo gynaecological and physical examination.

For security reasons, the hospital will conduct regular follow-up of any vaccine-induced adverse reactions. The vaccine may produce adverse reactions similar to ordinary vaccine, it security has received more than 100 countries.

"If the four hospitals project smoothly and the test results show 5 years involved in the pilot's women have HPV infection, the vaccine is expected to be 5 years after the universal access in the country. "Gliding East, global cervical cancer patients in each new issue is about 46 million people, accounting for a quarter of patients with China.